Bazemore Robert B 4

Accession 0001493152-25-028416

CIK 0001541157other

View on SEC.gov Company Profile

Filed

Dec 17, 7:00 PM ET

Accepted

Dec 18, 9:56 PM ET

Size

24.6 KB

Accession

0001493152-25-028416

Insider Transaction Report

Form 4

Period: 2025-12-16

Akari Therapeutics PlcAKTX

Bazemore Robert B

Director

Transactions

Purchase
Warrants to purchase American Depositary Shares ("ADRs")
2025-12-16+123,731→ 123,731 total
Exercise: $0.39→ American Depositary Shares representing Ordinary Shares (123,731 underlying)
Purchase
Pre-Funded Warrants to purchase ADRs
2025-12-16$0.40/sh+123,731$50,000→ 123,731 total
Exercise: $0.00→ American Depositary Shares representing Ordinary Shares (123,731 underlying)
Purchase
Warrants to purchase ADRs
2025-12-16+30,932→ 30,932 total
Exercise: $0.39→ American Depositary Shares representing Ordinary Shares (30,932 underlying)
Purchase
Pre-Funded Warrants to purchase ADRs
2025-12-16$0.40/sh+30,932$12,500→ 30,932 total
Exercise: $0.00→ American Depositary Shares representing Ordinary Shares (30,932 underlying)

Footnotes (7)

[F1]Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer.
[F2]On December 16, 2025, the Reporting Person acquired (i) unregistered pre-funded warrants to purchase up to 123,731 ADSs (the "PIPE PFWs" and ) and (ii) accompanying Series G Warrants to purchase up to 123,731 ADSs (the "Series G Warrants"), at a combined purchase price of $0.4041 per PIPE PFW and Series G Warrant in a private placement transaction pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended.
[F3]The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised.
[F4]The combined purchase price per one PIPE PFW and accompanying PIPE Series G Warrant was $0.4041.
[F5]On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the "Note Exchange Unregistered Pre-Funded Warrants") to purchase up to 30,932 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 32,191 ADSs (the "Note Exchange Unregistered Warrants").
[F6]The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised.
[F7]Conversion Exercise Price of Security is $0.00001

Documents

2 files

Issuer

Akari Therapeutics Plc

CIK 0001541157

→

Entity typeother

Related Parties

filerCIK 0001620152

Filing Metadata

Form type: 4
Filed: Dec 17, 7:00 PM ET
Accepted: Dec 18, 9:56 PM ET
Size: 24.6 KB

View on SEC.gov